Want to see TECX full AI Analyst Report?
TECX Stock Chart & Stats
$29.51
-$0.66(-1.42%)
At close: 4:00 PM EST
$29.51
-$0.66(-1.42%)
Day’s Range― - ―
52-Week Range$14.39 - $39.53
Previous CloseN/A
Volume30.18K
Average Volume (3M)167.88K
Market Cap
$669.48M
Enterprise Value$334.95M
Total Cash (Recent Filing)$236.89M
Total Debt (Recent Filing)$4.63M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 19, 2026EPS Estimate
-1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.46
Shares Outstanding18,869,186
10 Day Avg. Volume197,583
30 Day Avg. Volume167,879
Financial Highlights & Ratios
PEG Ratio-1.69
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-6.34
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.16
Forecast
1Y Price Target
$80.75Price Target Upside173.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong CapitalizationVery low debt and a sizable equity base provide durable financial flexibility for an R&D-stage biotech. This reduces near-term refinancing risk, supports continued investment in clinical programs, and extends runway compared with highly leveraged peers, aiding long-term program execution.
Platform + TX45 Trial ProgressCompletion of a 191-patient global Phase 2 trial materially de-risks development execution and demonstrates operational capability. Combined with a proprietary GPCR platform and a pipeline across multiple indications, this progress enhances the company's path to value creation beyond short-term market moves.
Strengthened Board / Capital Markets ExpertiseAdding a seasoned healthcare investment banker with decades of capital markets and M&A experience strengthens governance and strategic capability. That expertise is durable, improving access to financing, strategic partnering and transaction execution as the company advances multiple clinical programs.
Bears Say
Pre-revenue With Sustained Cash BurnThe company remains pre-revenue with persistent negative free cash flow and operating cash flow. Over the medium term this necessitates external financing or partnerships, creating dilution and execution risk if capital markets are constrained or deal terms are unfavorable.
Concentration On Single Late-stage ProgramA large portion of near-term value depends on the outcome of the TX45 Phase 2 trial. Clinical readouts are binary and can materially swing development plans, funding needs, and strategic options; reliance on one pivotal program raises structural execution risk for the company.
Accelerating Operating LossesOperating losses have increased markedly over recent years, reflecting rising development and operating spend. If this trajectory continues absent revenue or partnership inflows, it will accelerate equity dilution risk and pressure strategic flexibility to fund ongoing clinical programs.
Tectonic Therapeutic News
TECX FAQ
What was Tectonic Therapeutic Inc’s price range in the past 12 months?
Tectonic Therapeutic Inc lowest stock price was $14.38 and its highest was $39.53 in the past 12 months.
What is Tectonic Therapeutic Inc’s market cap?
Tectonic Therapeutic Inc’s market cap is $669.48M.
When is Tectonic Therapeutic Inc’s upcoming earnings report date?
Tectonic Therapeutic Inc’s upcoming earnings report date is Aug 19, 2026 which is in 41 days.
How were Tectonic Therapeutic Inc’s earnings last quarter?
Tectonic Therapeutic Inc released its earnings results on May 07, 2026. The company reported -$1.34 earnings per share for the quarter, missing the consensus estimate of -$1.165 by -$0.175.
Is Tectonic Therapeutic Inc overvalued?
According to Wall Street analysts Tectonic Therapeutic Inc’s price is currently Undervalued.
Does Tectonic Therapeutic Inc pay dividends?
Tectonic Therapeutic Inc does not currently pay dividends.
What is Tectonic Therapeutic Inc’s EPS estimate?
Tectonic Therapeutic Inc’s EPS estimate is -1.35.
How many shares outstanding does Tectonic Therapeutic Inc have?
Tectonic Therapeutic Inc has 18,869,186 shares outstanding.
What happened to Tectonic Therapeutic Inc’s price movement after its last earnings report?
Tectonic Therapeutic Inc reported an EPS of -$1.34 in its last earnings report, missing expectations of -$1.165. Following the earnings report the stock price went up 7.927%.
Which hedge fund is a major shareholder of Tectonic Therapeutic Inc?
Currently, no hedge funds are holding shares in TECX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tectonic Therapeutic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.75 (173.64% Upside)
$80.75 (173.64% Upside)
Blogger Sentiment
Bullish
TECX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 395.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.81%
12-Months-Change
Fundamentals
Return on Equity
-32.33%
Trailing 12-Months
Asset Growth
-21.68%
Trailing 12-Months
Company Description
Tectonic Therapeutic Inc
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
TECX Stock 12 Month Forecast
Average Price Target
$80.75
▲(173.64% Upside)
Technical Analysis
Omeros
―
Abeona Therapeutics
―
Mereo Biopharma Group Plc
―
Foghorn Therapeutics
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
35.62% Insiders
15.02% Mutual Funds
<0.01% Other Institutional Investors
43.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---